Dr. Deborah R. Alpert, MD

Dr. Alpert practices at Hmhmg Specialty Care in Hackensack, New Jersey.

Dr. Alpert's NPI, 1124150834, was assigned on March 9, 2007. Dr. Alpert graduated from New York University School of Medicine in 2001. Dr. Alpert holds New Jersey license 25MA08202800.

Dr. Alpert's primary practice is Hmhmg Specialty Care, at 360 Essex St, Hackensack, NJ 07601 in Bergen County. The practice phone is (732) 807-0800.

Dr. Alpert's primary practice is Hmhmg Specialty Care in Hackensack, New Jersey. Dr. Alpert is also affiliated with Jersey Shore University Medical Center. The medical group on file is Hackensack Meridian Medical Group. Dmand AI also links Dr. Alpert to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alpert practices, 7 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Alpert's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Alpert is board certified in rheumatology by the American Board of Internal Medicine. Dr. Alpert is licensed in New Jersey.

CMS data shows 46,020 Medicare services from Dr. Alpert across 18 procedure codes in 2024, for 355 Medicare patients. Medicare paid $304,628 for them.

CMS counts 355 Medicare patients who saw Dr. Alpert in 2024. The largest group is 65 to 74, with 174 patients. 75% of them have arthritis, and 75% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alpert's median patient age at 67, with 80% women.

In 2024, Dr. Alpert wrote 1,415 Medicare Part D claims for 291 patients. 80% of them were for generic drugs. CMS names the drug for 1,227 of them, across 29 drugs with 11 or more claims each, at $1,419,021 in total drug cost. In 2023, CMS named 1,180 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Alpert for performance year 2024, reported as part of a group. Dr. Alpert accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Alpert, published from 2011 to 2021. 2021 was the busiest year, with 2. The most frequent topics are Anti-Inflammatory Agents, Immunosuppressive Agents and Mycophenolic Acid. Dr. Alpert has published most often in BMJ Case Rep. Dr. Alpert's most frequent co-authors are Abbas Alshami, MD, Dawn M. Calderon, DO and Richard Michael Abramowitz, MD.

Dmand AI links Dr. Alpert to 1 clinical trial. Conditions studied include Spondylitis, Ankylosing and Axial Spondyloarthritis.

CMS Open Payments shows 596 general payments to Dr. Alpert from 56 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 51% of the total. Abbvie Inc. paid the most, $39,333.

Dr. Alpert graduated from New York University School of Medicine in 2001.